The risk of malignancy in patients with secukinumab-treated psoriasis, psoriatic arthritis and ankylosing spondylitis. van de Kerkhof PCM. Br J Dermatol 2021 Aug 17. doi: 10.1111/bjd.20624.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

van de Kerkhof PCM. The risk of malignancy in patients with secukinumab-treated psoriasis, psoriatic arthritis and ankylosing spondylitis. Br J Dermatol 2021 Aug 17. doi: 10.1111/bjd.20624.
PMID: 34402525